Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
Public ClinicalTrials.gov record NCT00546793. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I/II Study of Subcutaneously Administered Veltuzumab (hA20) in Patients With CD20+ Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine if a subcutaneous (SC) dosing schedule of veltuzumab can be established in NHL or CLL patients and to confirm the safety and efficacy of veltuzumab that was previously established when administered intravenously.
Study identification
- NCT ID
- NCT00546793
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 32 participants
Conditions and interventions
Conditions
- NHL
- Lymphoma, Non-Hodgkin
- Lymphoma, B-Cell
- Lymphoma, Follicular
- Lymphoma, Intermediate-Grade
- Lymphoma, Large-Cell
- Lymphoma, Low-Grade
- Lymphoma, Mixed-Cell
- Lymphoma, Small-Cell
- Leukemia, Lymphocytic, Chronic
- Leukemia, B-Cell, Chronic
- Leukemia, Prolymphocytic
- Leukemia, Small Lymphocytic
- Lymphoma, Small Lymphocytic
- Lymphoma, Lymphoplasmacytoid, CLL
- Lymphoplasmacytoid Lymphoma, CLL
- CLL
- SLL
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2008 (Type not available)
- Primary completion
- Mar 2013 (Actual)
- Completion
- Mar 2013 (Actual)
- Last update posted
- Aug 16, 2021
2008 – 2013
United States locations
- U.S. sites
- 5
- U.S. states
- 4
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Lewis Cancer Center and Research Pavilion | Savannah | Georgia | 31405 | — |
| Cancer Care at Saint Clare's/Saint Clares Hospital Oncology & Hematology Specialists, P.A. | Denville | New Jersey | 07834 | — |
| Morristown Memorial Hospital | Morristown | New Jersey | 07950 | — |
| New York Hospital Weill Cornell Medical Center | New York | New York | 10021 | — |
| Cleveland Clinic Taussig Cancer Center | Cleveland | Ohio | 44195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00546793, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 16, 2021 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00546793 live on ClinicalTrials.gov.